Form 4: AbbVie Director Jennifer L. Davis Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Jennifer L. Davis reports acquisition of 1,322 restricted stock units in AbbVie Inc. on May 3, 2024.
Summary
- On May 3, 2024, Jennifer L. Davis, a director of AbbVie Inc., acquired 1,322 restricted stock units (RSUs).
- These RSUs were awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program.
- The RSUs will be paid out in shares of AbbVie common stock on a one-to-one basis upon the earlier of the director's separation from service, death, or a change in control as defined in the Program.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock ownership, and does not contain information that would significantly impact investor sentiment.
Future Outlook
The restricted stock units will be paid out in shares of AbbVie common stock on the earlier of the director's separation from service, death, or a change in control as defined in the Program.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of restricted stock units by a director aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/03/2024 | Date of transaction: Acquisition of restricted stock units |
| 05/07/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.